Immunology

Making immunotherapy safe for AML

Acute myeloid leukemia (AML), the second most common leukemia in children, is hard to treat and has a five-year survival rate of just 65 to 70%, according to the American Cancer Society. While immunotherapies like monoclonal ...

Medical research

Resistance mechanisms to CAR-T cell therapy ID'd in ALL

For patients with acute lymphoblastic leukemia with resistance to C19 CAR T-cell therapy, resistance mechanisms that can be detected prior to treatment have been identified, according to a study presented at the annual meeting ...

Medical research

Genetically encoded sensor isolates hidden leukemic stem cells

All stem cells can multiply, proliferate and differentiate. Because of these qualities, leukemic stem cells are the most malignant of all leukemic cells. Understanding how leukemic stem cells are regulated has become an important ...

Oncology & Cancer

Closer to identifying leukemic stem cells

Acute myeloid leukemia is the most common type of leukemia in adults. It is characterized by the pathological expansion of immature cells (myeloblasts) that invade the bone marrow and expand into the blood, affecting the ...

Oncology & Cancer

Leukemia cells are addicted to a healthy gene

What keeps leukemia cells alive almost forever, able to continue dividing endlessly and aggressively? New research at the Weizmann Institute suggests that, in around a quarter of all leukemias, the cancer cells rely on an ...

page 2 from 8